美国 · SEC FORM 4
BeOne Medicines Ltd.
ONC · Nasdaq; OTC · CIK 0001651308 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
196 同一窗口内观察到的 Form 4 交易行
154 sales · 42 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2021-09-10 · AMGEN INC.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 1,933,092
- 上期报告
- 1,707,474
- 日均成交量
- 389,451
- 回补天数
- 5.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2021-09-10 | AMGEN INC | 买入 (P) | American Depositary Shares | 165,529 | USD 302.06 | USD 49,999,690 | SEC 申报 ↗ |
Form 4 申报证据
280 transaction lines in the latest 365-day window; 1,627 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Wang Xiaodong | 卖出 (S) | American Depositary Shares | 31,027 | USD 350.99 | USD 10,890,074 | SEC 申报 ↗ |
| 2026-10-13 | Wang Xiaodong | 期权行权/转换 (M) | American Depositary Shares | 31,027 | USD 36.90 | USD 1,144,896 | SEC 申报 ↗ |
| 2026-09-30 | Lee Chan Henry | 卖出 (S) | American Depositary Shares | 1,115 | USD 375.00 | USD 418,125 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Wang Xiaodong | 卖出 (S) | American Depositary Shares | 31,027 | USD 350.99 | USD 10,890,074 | SEC 申报 ↗ |
| 2026-10-13 | Wang Xiaodong | 期权行权/转换 (M) | American Depositary Shares | 31,027 | USD 36.90 | USD 1,144,896 | SEC 申报 ↗ |
| 2026-09-30 | Lee Chan Henry | 卖出 (S) | American Depositary Shares | 1,115 | USD 375.00 | USD 418,125 | SEC 申报 ↗ |
| 2026-09-28 | Wang Xiaodong | 卖出 (S) | American Depositary Shares | 31,028 | USD 364.79 | USD 11,318,606 | SEC 申报 ↗ |
| 2026-09-28 | Wang Xiaodong | 期权行权/转换 (M) | American Depositary Shares | 31,028 | USD 36.90 | USD 1,144,933 | SEC 申报 ↗ |
| 2026-09-14 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 期权行权/转换 (M) | American Depositary Shares | 30,768 | USD 36.83 | USD 1,133,185 | SEC 申报 ↗ |
| 2026-09-08 | Wang Xiaodong | 卖出 (S) | American Depositary Shares | 38,287 | USD 349.10 | USD 13,365,964 | SEC 申报 ↗ |
| 2026-09-08 | Wang Xiaodong | 期权行权/转换 (M) | American Depositary Shares | 31,027 | USD 36.90 | USD 1,144,896 | SEC 申报 ↗ |
| 2026-09-01 | Ball Titus B. | 卖出 (S) | American Depositary Shares | 132 | USD 355.86 | USD 46,974 | SEC 申报 ↗ |
| 2026-08-25 | Wu Xiaobin | 卖出 (S) | American Depositary Shares | 280 | USD 380.00 | USD 106,400 | SEC 申报 ↗ |
| 2026-08-12 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 54,892 | USD 358.15 | USD 19,659,540 | SEC 申报 ↗ |
| 2026-08-11 | Lee Chan Henry | 卖出 (S) | American Depositary Shares | 2,666 | USD 360.00 | USD 959,760 | SEC 申报 ↗ |
| 2026-08-11 | Lee Chan Henry | 期权行权/转换 (M) | American Depositary Shares | 2,666 | USD 191.37 | USD 510,190 | SEC 申报 ↗ |
| 2026-08-11 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 70,907 | USD 361.90 | USD 25,661,365 | SEC 申报 ↗ |
| 2026-08-10 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 115,011 | USD 357.88 | USD 41,159,726 | SEC 申报 ↗ |
| 2026-08-03 | Rosenberg Aaron | 卖出 (S) | American Depositary Shares | 1,157 | USD 312.72 | USD 361,817 | SEC 申报 ↗ |
| 2026-07-30 | Lee Chan Henry | 卖出 (S) | American Depositary Shares | 1,044 | USD 323.69 | USD 337,932 | SEC 申报 ↗ |
| 2026-07-22 | Lee Chan Henry | 卖出 (S) | American Depositary Shares | 1,669 | USD 325.00 | USD 542,425 | SEC 申报 ↗ |
| 2026-07-22 | Lee Chan Henry | 期权行权/转换 (M) | American Depositary Shares | 1,669 | USD 191.58 | USD 319,740 | SEC 申报 ↗ |
| 2026-07-21 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 61,397 | USD 317.67 | USD 19,504,082 | SEC 申报 ↗ |
| 2026-07-20 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 48,316 | USD 312.26 | USD 15,086,929 | SEC 申报 ↗ |
| 2026-07-20 | OYLER JOHN | 期权行权/转换 (M) | American Depositary Shares | 33,990 | USD 119.96 | USD 4,077,440 | SEC 申报 ↗ |
| 2026-07-17 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 64,628 | USD 312.00 | USD 20,163,749 | SEC 申报 ↗ |
| 2026-07-17 | OYLER JOHN | 期权行权/转换 (M) | American Depositary Shares | 64,628 | USD 119.96 | USD 7,752,775 | SEC 申报 ↗ |
| 2026-07-16 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 166,597 | USD 318.09 | USD 52,992,334 | SEC 申报 ↗ |
| 2026-07-16 | OYLER JOHN | 期权行权/转换 (M) | American Depositary Shares | 166,597 | USD 143.38 | USD 23,887,477 | SEC 申报 ↗ |
| 2026-07-15 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 116,557 | USD 311.94 | USD 36,359,316 | SEC 申报 ↗ |
| 2026-07-15 | OYLER JOHN | 期权行权/转换 (M) | American Depositary Shares | 116,557 | USD 148.00 | USD 17,250,520 | SEC 申报 ↗ |
| 2026-07-14 | OYLER JOHN | 卖出 (S) | American Depositary Shares | 145,861 | USD 305.95 | USD 44,626,082 | SEC 申报 ↗ |
| 2026-07-14 | OYLER JOHN | 期权行权/转换 (M) | American Depositary Shares | 133,600 | USD 54.06 | USD 7,222,959 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ONC |
| CIK | 0001651308 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq; OTC |
数据覆盖
| 本地 Form 4 历史 | 1,627 transaction lines from 2020-01-21 to 2026-10-13 1 P purchase lines · 1,335 S sale lines · 291 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.